Back

Plasma glucosylceramide levels are regulated by ATP10D and are not involved in Parkinson's disease pathogenesis.

Somerville, E. N.; James, A.; Beatz, C.; Schwieger, R.; Barrel, G.; Kandaswamy, K. K.; Iurascu, M. I.; Bauer, P.; Ta, M.; Iwaki, H.; Senkevich, K.; Yu, E.; Alcalay, R. N.; Gan-Or, Z.

2024-09-14 genetic and genomic medicine
10.1101/2024.09.13.24313644 medRxiv
Show abstract

GBA1 variants and decreased glucocerebrosidase (GCase) activity are implicated in Parkinsons disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), one of GCase main substrates, are involved in PD pathogenesis. Using multiple genetic methods, we show that ATP10D, not GBA1, is the main regulator of plasma GlcCer levels, yet it is not involved in PD pathogenesis. Plasma GlcCer levels were associated with PD, but not in a causative manner, and are not predictive of disease status. These results argue against targeting GlcCer in GBA1-PD and underscore the need to explore alternative mechanisms and biomarkers for PD.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.